Blood Screening Market Size & Growth Forecast 2027–2036, By Segments (Product, End-use, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Blood Screening Market size was more than USD 3.83 Billion in 2026 and is set to grow at 7.74% CAGR between 2027 and 2036, attaining USD 8.07 Billion by 2036. The industry revenue for 2027 is assessed at USD 4.08 Billion.

• Base Year Value (2026): USD 3.83 Billion
• CAGR (2027-2036): 7.74%
• Forecast Year Value (2036): USD 8.07 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Blood Screening Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America led in 2025 through advanced laboratory infrastructure, stringent transfusion safety practices, diagnostic investment, automation, and established blood donation networks.
  • Asia Pacific is expanding rapidly as healthcare systems modernize, blood donation programs grow, and governments strengthen screening, laboratory infrastructure, and testing capabilities.

• Segment Momentum:

  • Blood banks held a 56.29% market share in 2025 due to high testing volumes for donated blood, ensuring transfusion safety and compliance with stringent blood screening standards.
  • Next generation sequencing is expanding quickly as laboratories seek comprehensive molecular analysis, advanced pathogen detection, and greater precision through detailed genomic information within blood screening workflows.

• Market Expansion Drivers:

  • Rising infectious disease prevalence driving demand for advanced blood safety and screening systems
  • Technological advancements in rapid and automated blood testing improving diagnostic accuracy
  • Growing blood transfusion volumes increasing need for stringent donor screening and safety protocols

• Leading Market Participants:

  Leading players in the blood screening market include Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Grifols, S.A. (Spain), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (United States), Danaher Corporation (United States), Bio-Rad Laboratories, Inc. (United States), QIAGEN N.V. (Netherlands), Hologic, Inc. (United States), QuidelOrtho Corporation (United States)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 3.83 Billion
  • 2027 Estimated Market Size: USD 4.08 Billion
  • Projected Market Size: USD 8.07 Billion by 2036
  • Growth Forecasts: 7.74% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Reagents & Kits (Product) | Blood Banks (End-use) | Nucleic Acid Test (Technology)
  • Emerging Opportunity Segment: Instruments (Product) | Pathology Laboratories (End-use) | Next Generation Sequencing (Technology)

Market Growth Drivers and Industry Trends

Rising infectious disease prevalence driving demand for advanced blood safety and screening systems

The growing burden of infectious diseases across both developed and emerging healthcare systems is creating sustained demand for reliable blood testing solutions, which will drive the blood screening market growth. Blood banks, hospitals, and transfusion centers are strengthening screening protocols to reduce the risk of transmitting pathogens through donated blood, particularly as healthcare providers face evolving infectious threats. Regulatory authorities are also reinforcing quality standards for blood safety, encouraging the adoption of highly sensitive screening technologies capable of detecting infections at earlier stages. This environment supports greater utilization of advanced testing platforms, reagent kits, and confirmatory assays across routine donor screening workflows while reinforcing the importance of comprehensive laboratory quality assurance practices.

Technological advancements in rapid and automated blood testing improving diagnostic accuracy

Continuous innovation in laboratory automation and rapid testing technologies is transforming blood screening workflows, with the blood screening market benefiting from faster turnaround times and improved analytical performance. Modern screening platforms integrate automated sample handling, high-throughput processing, and sophisticated detection methods that reduce manual intervention while improving consistency and minimizing the potential for human error. Enhanced sensitivity and specificity enable laboratories to identify infectious markers with greater confidence, supporting safer transfusion practices and more efficient clinical decision-making. The integration of digital laboratory management tools further streamlines operations by improving data traceability, workflow efficiency, and standardized reporting across diagnostic facilities.

Growing blood transfusion volumes increasing need for stringent donor screening and safety protocols

As healthcare systems perform a greater number of blood transfusions for surgical procedures, trauma care, chronic illnesses, and emergency medicine, the blood screening market will experience stronger demand for comprehensive donor evaluation and testing procedures. Higher transfusion activity requires blood collection agencies to maintain consistent screening standards that ensure compatibility and minimize the transmission of infectious agents. This operational need encourages investments in validated screening assays, standardized testing protocols, and laboratory infrastructure capable of handling larger sample volumes without compromising quality. Healthcare providers also place increasing emphasis on traceability, donor eligibility assessment, and quality control measures to maintain the integrity of national and regional blood supply networks.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising infectious disease prevalence driving demand for advanced blood safety and screening systems	2%	High	North America, Asia Pacific	High	Near Term
Technological advancements in rapid and automated blood testing improving diagnostic accuracy	1.7%	High	North America, Europe	High	Near Term
Growing blood transfusion volumes increasing need for stringent donor screening and safety protocols	1.5%	High	Global	High	Near Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America dominated the blood screening market in 2026, supported by highly developed healthcare systems, advanced laboratory infrastructure, and strong emphasis on transfusion safety. Comprehensive screening practices and stringent quality requirements encourage healthcare institutions and blood centers to adopt sophisticated testing technologies for identifying infectious diseases and ensuring the safety of donated blood. Continued investment in diagnostic infrastructure, laboratory automation, and advanced molecular testing is strengthening screening capabilities. The region’s established blood donation networks and emphasis on reducing transfusion-related risks further contribute to sustained demand for reliable screening solutions.

Asia Pacific is anticipated to experience the fastest growth as healthcare systems expand and blood safety practices become more sophisticated across the region. Increasing awareness of transfusion-transmitted infections is encouraging governments and healthcare institutions to strengthen screening procedures and laboratory capabilities. Expanding blood donation programs and the modernization of diagnostic facilities are creating additional demand for advanced screening technologies. Improvements in healthcare accessibility, increasing investment in laboratory infrastructure, and greater adoption of automated and molecular testing methods are also supporting the transition toward more comprehensive blood safety practices.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Product Segment Analysis: Reagents & Kits (Largest Segment) vs Instruments (Fastest-Growing Segment)

The reagents & kits segment dominated the blood screening market with a share of 72% in 2026. Its leading position is supported by the recurring need for consumables across routine blood safety testing, infectious disease screening, and diagnostic workflows. Continuous testing requirements across healthcare facilities and blood collection centers generate sustained demand for reagents and kits, while ongoing improvements in assay sensitivity and workflow efficiency further reinforce their widespread adoption.

The instruments segment is expected to witness the fastest growth as laboratories increasingly modernize testing infrastructure through automated and high-throughput screening systems. Growing emphasis on operational efficiency, faster turnaround times, and improved diagnostic accuracy is encouraging investment in advanced analytical platforms. Continued technological innovation and expanding laboratory automation are expected to accelerate adoption of sophisticated blood screening instruments.

End-use Segment Analysis: Blood Banks (Largest Segment) vs Pathology Laboratories (Fastest-Growing Segment)

The blood banks segment held the largest share of 56.29% in 2026. Blood banks routinely perform comprehensive screening of donated blood to maintain transfusion safety and regulatory compliance, resulting in consistently high testing volumes. The expansion of voluntary blood donation programs, combined with stringent quality standards for blood products, continues to support the segment's dominant position.

The pathology laboratories segment is anticipated to record the fastest growth due to increasing demand for specialized diagnostic services and expanding adoption of advanced laboratory technologies. Rising testing requirements for infectious diseases, greater laboratory automation, and the growing role of centralized diagnostic facilities are contributing to higher utilization of blood screening procedures within pathology laboratories.

Technology Segment Analysis: Nucleic Acid Test (Largest Segment) vs Next Generation Sequencing (Fastest-Growing Segment)

In the blood screening market, the nucleic acid test segment accounted for the largest share of 45.58% in 2026. Its strong market position is driven by its ability to detect infections at an early stage with high sensitivity, supporting safer blood transfusion practices. Widespread implementation in blood donor screening programs and its effectiveness in reducing the risk of transfusion-transmitted infections continue to underpin its extensive adoption.

The next generation sequencing segment is expected to grow the fastest as healthcare providers and laboratories increasingly seek comprehensive molecular analysis with greater precision. Its capability to identify multiple genetic targets simultaneously, support advanced pathogen detection, and generate detailed genomic information is expanding its role in blood screening. Continued technological progress and broader integration into precision diagnostic workflows are expected to strengthen adoption of next generation sequencing technologies.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Reagents & Kits, Instruments	Reagents & Kits	Instruments
End-use	Hospitals, Blood Banks, Pathology Laboratories	Blood Banks	Pathology Laboratories
Technology	Nucleic Acid Test, Serology/immunoassays, Rapid Test, Western Blot Assays, Next Generation Sequencing	Nucleic Acid Test	Next Generation Sequencing

Competitive Landscape and Market Positioning

Prominent players in the blood screening market:

1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche AG (Switzerland)
3. Grifols S.A. (Spain)
4. Siemens Healthineers AG (Germany)
5. Thermo Fisher Scientific, Inc. (United States)
6. Danaher Corporation (United States)
7. Bio-Rad Laboratories, Inc. (United States)
8. QIAGEN N.V. (Netherlands)
9. Hologic, Inc. (United States)
10. QuidelOrtho Corporation (United States)

The blood screening market is evolving toward competition based on diagnostic accuracy, laboratory efficiency, and the ability to support increasingly complex testing environments. Suppliers are refining assay technologies and automation capabilities to help laboratories manage higher testing demands while maintaining consistency across diverse sample volumes and regulatory frameworks. At the same time, greater emphasis on integrated laboratory workflows is encouraging manufacturers to develop solutions that simplify data management, reduce manual intervention, and improve compatibility with existing diagnostic infrastructure. These changes are steadily shifting competitive emphasis from individual testing platforms toward comprehensive screening ecosystems that enhance operational reliability and quality assurance across blood safety programs.

Industry Development/News

Company Name	Date	Key Development
Abbott	Mar-26	Abbott completed a US$21 billion acquisition of Exact Sciences, significantly consolidating the molecular diagnostics sector. The transaction enhances Abbott's long-term competitive positioning by integrating advanced cancer screening and testing capabilities into its global diagnostic portfolio.
Roche Diagnostics Korea	Feb-26	South Korea's Ministry of Food and Drug Safety granted regulatory approval for Roche Diagnostics Korea's cobas Malaria NAT blood screening test. The integration of nucleic acid testing enables the formal detection of five malaria parasites in donated blood, improving safety protocols.
AIIMS Nagpur	Nov-25	AIIMS Nagpur expanded its operational infrastructure through the inauguration of advanced blood safety facilities. The expansion includes an Individual Donor-Nucleic Acid Testing laboratory and a Blood Irradiator Unit, boosting regional capacity for high-throughput, safe transfusion screening.
Guardant Health	Jul-24	Guardant Health secured U.S. FDA approval for its Shield blood test, addressing colorectal cancer screening for average-risk adults. The regulatory milestone commercializes a non-invasive, blood-based screening method that alters competitive dynamics within the early cancer detection market landscape.
Quest Diagnostics	Jul-23	Quest Diagnostics commercialized its consumer-initiated AD-Detect blood screening test for Alzheimer's disease. The test evaluates specific brain proteins to assess risk, expanding the market footprint for direct-to-consumer neurological screening services.
Abbott	Mar-23	Abbott secured U.S. FDA approval for its laboratory traumatic brain injury blood screening test deployed on the Alinity I laboratory device. The commercial release establishes a rapid, objective diagnostic protocol for mild TBIs within institutional hospital networks.